OAR 333-007-0360
Sampling and Sample Size Requirements for Compliance Testing

(1) Marijuana or usable marijuana.
(a) Usable marijuana may only be sampled after it is cured, unless the usable marijuana is intended for sale or transfer to a processor or processing site to make a cannabinoid concentrate or extract.
(b) Sample increments taken must in total represent a minimum of 0.5 percent of the batch, consistent with the laboratory’s accredited sampling policies and procedures, described in OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing)(2).
(c) A portion of sample increments taken from multiple batches of usable marijuana from the same harvest lot may be combined into one sample for purposes of testing for THC and CBD if the batches are the same strain, regardless of the size of the multiple batches.
(2) Cannabinoid concentrates, extracts and products.
(a) Samples of cannabinoid concentrates, extracts and products intended for human consumption, use or ingestion for use by a consumer or patient must be taken from the finished cannabinoid concentrate, extract or product as those terms are defined in OAR 333-007-0310 (Definitions).
(b) Until a control study has been certified under OAR 333-007-0440 (Control Study), the minimum number of sample increments that must be taken are established in Exhibit B, Table 5 or 6, incorporated by reference. Enough sample increments from a batch must be taken to determine whether the batch is homogeneous and must be taken in a manner consistent with the laboratory’s accredited sampling policies and procedures described in OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing)(2).
(c) If a cannabinoid concentrate or extract has a certified control study, the minimum number of sample increments that must be taken for future batches of that concentrate or extract are established in Exhibit B, Table 7, incorporated by reference. The sample increments may be combined into a primary sample and a field duplicate sample in accordance with OAR 333-007-0440 (Control Study)(9) and OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing)(2). The primary sample and the field duplicate sample must be prepared and analyzed separately.
(d) For a cannabinoid product that has a certified control study, at a minimum one unit of sale chosen at random, is required for the primary sample and one unit of sale chosen at random, is required for the field duplicate sample for testing future batches of that product in accordance with OAR 333-007-0440 (Control Study)(9) and OAR 333-064-0100 (Marijuana Item Sampling Procedures and Testing)(2). The primary sample and the field duplicate sample must be prepared and analyzed separately.
(e) A sufficient sample size must be taken for analysis of all requested tests and the quality control performed by the testing laboratory for these tests.
(3) Sufficient sample increments must be taken for analysis of all required tests and the quality control performed by the testing laboratory for these tests.
[ED. NOTE: To view attachments referenced in rule text, click here to view rule.]

Source: Rule 333-007-0360 — Sampling and Sample Size Requirements for Compliance Testing, https://secure.­sos.­state.­or.­us/oard/view.­action?ruleNumber=333-007-0360.

Last Updated

Jun. 8, 2021

Rule 333-007-0360’s source at or​.us